Study to Evaluate the Safety and Efficacy of PAZ320 in Patients With Type 2 Diabetes (PAZ320)

Study to Evaluate the Safety and Efficacy of PAZ320 When Added to Oral Agents or Insulin in Patients With Type 2 Diabetes Mellitus

This study is to evaluate the effect that PAZ320 has on post-prandial glucose excursions measured via continuous glucose monitoring and its adverse effect profile in humans.

Study Overview

• Status: Completed
• Conditions: Type 2 Diabetes Treated With Insulin
• Intervention / Treatment: Drug: PAZ320

Detailed Description

In this study, the investigators seek to evaluate the effect that PAZ320 has on post-prandial glucose excursions measured via continuous glucose monitoring and its adverse effect profile in humans. Continuous glucose monitors (CGM) are minimally invasive devices that measure glucose levels in interstitial fluid. A small wire is inserted subcutaneously which transmits the ambient subcutaneous glucose concentration every 5 minutes to a wireless recorder. In usual use, the patient can see these data and graph the previous 1, 3 or 9 hours to identify trends or look back over time (ie over night). In our study, the patient will be blinded to the data so as not to confound results, as it has been noted in another study that patient's blood sugar control was better when they were able to see CGM results and modified their diet. CGM's have been shown to have clinical accuracies of 95.5-98.9% and have been used in clinical trials and found to be safe. Having the patient do a finger-stick glucose intermittently during the time they are wearing the CGM improves accuracy.

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • New Hampshire
    • Dartmouth, New Hampshire, United States, 03755
      • Dartmouth-Hitchcock Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female subjects, aged 18-75 years;
• Subjects diagnosed with Type 2 Diabetes mellitus;
• Subjects currently on oral agents or insulin;
• Body mass index 25 to 40 kg/m2;
• Subjects able to comply with study procedures and sign informed consent
• A1c less than or equal to 9%

Exclusion Criteria:

• Medication (other than diabetes medications or insulin) or dietary supplement known to affect glucose or galactose metabolism
• Use of acetaminophen-containing products
• Lactose or galactose intolerance
• History of eating disorder
• Food allergy or severe food intolerance
• Pregnant or lactating female
• Subjects with diabetes mellitus treated with very high dose of sulfonylureas (glyburide>20 mg/day, , glimepiride >8 mg per day, and glipizide >20 mg per day) α-glucosidase inhibitors (acarbose ), or meglitinides (repaglinide >6 mg per day)), ;
• Subject with gastrointestinal disease that may interfere with absorption of the investigational products at discretion of investigator, including but are not limited to malabsorption syndromes and gastric ulcer;
• Subject has received any investigational agent within 30 days prior to the first dose of investigational product

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: Single

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PAZ320; Patients will all take part in the control arm of the study and then be crossed over into treatment with PAZ320 at two different dosages.	Drug: PAZ320; Single-center pilot study, open label dose escalation design

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
To evaluate the efficacy of the food supplement PAZ320 on post-prandial glucose excursion	1 week

Secondary Outcome Measures

Outcome Measure	Time Frame
Number of Subjects with Adverse Events as a Measure of Safety and Tolerability	1 week

Collaborators and Investigators

• Sponsor: Boston Therapeutics
• Investigators: Principal Investigator: Laura E Trask, MD, Dartmouth-Hitchcock Medical Center

Study record dates

Study Major Dates

• Study Start: March 1, 2011
• Primary Completion (Actual): August 1, 2011
• Study Completion (Actual): August 1, 2011

Study Registration Dates

• First Submitted: November 18, 2013
• First Submitted That Met QC Criteria: February 11, 2014
• First Posted (Estimate): February 12, 2014

Study Record Updates

• Last Update Posted (Estimate): February 13, 2014
• Last Update Submitted That Met QC Criteria: February 12, 2014
• Last Verified: February 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Physiological Effects of Drugs; PAZ320
• Other Study ID Numbers: PAZ320-002